Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (31102)	2/28/2000 6:58:00 AM
From: SSP	Respond to of 150070

Lorus Therapeutics' Lead Anti-Cancer Drugs Reduce Tumor Growth in Mouse Models With Human Prostate Cancer Cells TORONTO, Feb 28, 2000 (BUSINESS WIRE) -- (TSE:LOR.) (OTC Bulletin Board:LORFF) Clinical trial with GTI-2040 currently in progress Lorus Therapeutics Inc. ("Lorus") announced today that its two lead anti-cancer drugs, GTI-2040 and GTI-2501, showed significant anti-tumor activity in mouse models containing human prostate cancer cells. While both drugs produced marked reductions in tumor growth, the GTI-2501 treatment also led to disease stabilization (i.e. very little or no tumor growth). These results were obtained in tests using two different human prostate tumor types on a total of 20 mice that received either GTI-2040 or GTI-2501. "Prostate cancer is one of the most common cancers in North America with, for example, nearly 900,000 new cases in the United States over the last four years. It may be treated successfully by surgery, radiation or hormonal therapies, but if the disease progresses to an advanced stage or recurs there are very few therapeutic options available," said Dr. Jim A. Wright, president and chief scientific officer at Lorus. "Clearly, it is important to find new drugs that are effective in treating prostate cancer, particularly the advanced forms, and from this point of view the pre-clinical results obtained with GTI-2040 and GTI-2501 are encouraging." The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug application to conduct clinical trials with GTI-2040. A clinical trial is now in progress and patient treatment with GTI-2040 is taking place under the direction of Dr. Richard Schilsky, Professor of Medicine and Associate Dean for Clinical Research at the University of Chicago Cancer Research Center. Although still early in the clinical trial, human dosing to date has been well tolerated with no apparent safety concerns. Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, thalliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual reports and 20-F filings. Lorus Therapeutics Inc.'s press releases are available through the company's Internet site: www.lorusthera.com. Copyright (C) 2000 Business Wire. All rights reserved. Distributed via COMTEX. -0- CONTACT: Investor Relations Karen Meagher, 416/ 599-8429 (FAX) Email: kmeagher@mcipr.com or Media Relations Julija Hunter or Pereina Choudhury, 416/ 599-7484 (FAX) Email: jhunter@mcipr.com or pchoudhury@mcipr.com